Large scale production Prati-Donaduzzi operates at a high capacity with up to 9 billion doses per year, indicating substantial manufacturing throughput and potential demand for supply chain, contract manufacturing services, or critical raw materials across scales.

Extensive portfolio With more than 180 medicines registered with ANVISA, there are multiple product lines and potential cross-sell opportunities for formulation development, packaging innovations, regulatory support, and geographic expansion partnerships.

Sustainability focus The company highlights sustainable growth and ongoing investments in quality, implying openness to solutions that improve efficiency, reduce waste, or lower total cost of ownership in manufacturing and supply chain.

Innovation culture A strong emphasis on training and daily pursuit of new ideas suggests opportunities for collaboration in research support, digital tooling adoption, analytics services, and unlocks potential for partnerships in tech-enabled drug development.

Strategic visibility Public initiatives such as health awareness campaigns and notable partnerships (for example with Shell) indicate potential for co-branded programs, CSR-aligned campaigns, and opportunities to engage in market education and patient access projects.